Form 4: Abbott Director Receives Restricted Stock Unit Award
Statement of Changes in Beneficial Ownership
Abbott Laboratories Director Claire Babineaux-Fontenot was granted 2,286 restricted stock units under the 2026 Incentive Stock Program.
Summary
- Director Claire Babineaux-Fontenot acquired 2,286 restricted stock units (RSUs) on April 24, 2026.
- The award was granted under the Abbott Laboratories 2026 Incentive Stock Program.
- The RSUs will be settled in common shares on a one-to-one basis upon the director's separation from service, death, or a change in control.
- Following this transaction, the director's total beneficial ownership is 7,603 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation with no material impact on company operations or financial outlook.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- None identified.
Risks
- None identified.
Future Outlook
The restricted stock units are subject to future settlement based on the director's separation from service, death, or a change in control of the company.
Management Comments
- The award is granted under the Abbott Laboratories 2026 Incentive Stock Program.
Industry Context
StockSavvy.ai notes that equity grants to board members are standard corporate governance practice to ensure alignment between leadership and shareholders in the healthcare and medical device sector.
Comparison to Industry Standards
- The use of restricted stock units for director compensation is consistent with standard practices at large-cap healthcare companies like Medtronic, Johnson & Johnson, and Stryker.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Appointment of Elizabeth C. Cushman, Jessica H. Paik, and Aaron N. Rice as attorneys-in-fact for SEC filings. | 06/13/2025 | Administrative update to facilitate regulatory compliance. |
Stakeholder Impact
- Minimal impact on shareholders as this is a standard director compensation event.
Next Steps
- The director will hold the units until separation from service, death, or a change in control.
Key Dates
| Date | Description |
|---|---|
| 06/13/2025 | Date of Power of Attorney execution. |
| 04/24/2026 | Date of the restricted stock unit grant transaction. |
| 04/28/2026 | Date of filing. |
Keywords
Abbott Laboratories, ABT, Form 4, Director Compensation, Restricted Stock Units, Insider Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.